Detalles de la búsqueda
1.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 391(10122): 748-757, 2018 02 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29268948
2.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet
; 389(10064): 67-76, 2017 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27939400
3.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Lancet
; 387(10031): 1909-20, 2016 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26952546
4.
The Diagnosis and Treatment of Patients With Bladder Carcinoma.
Dtsch Arztebl Int
; 118(Forthcoming)2020 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33759759
5.
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
Eur Urol
; 73(3): 462-468, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29273410
6.
Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8].
Eur Urol
; 75(3): e82-e83, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30502102
7.
CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells.
Int J Cancer
; 114(2): 182-9, 2005 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-15540205
Resultados
1 -
7
de 7
1
Próxima >
>>